Phase 3 N=342 Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation
Vitamin D3 Deficiency
Primary: Number of Participants With Greater Than 100 Nmol/L 25(OH)D (Converted Vitamin D) — 110; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=151 Tinnitus Retraining Therapy Trial
Subjective Tinnitus
Primary: Change in Tinnitus Questionnaire (TQ) From Baseline to 3, 6, 12, and 18 Months — -17.8; -15.4; -11.5; -22.0 units on a scale — p=0.47
Phase 3 N=420 Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP — 19.17; 19.61; 18.46; 19.22 mm Hg — p=0.216
N/A N=2,209 Hepatitis C Testing in VA Community-Based Outpatient Clinics
Hepatitis C
Primary: HCV Antibody Test — 574 Participants
Phase 4 N=45 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
Type 1 Diabetes · Diabetic Nephropathy · Diabetic Kidney Disease
Primary: Change in Urine Uric Acid Concentration (Increased Solubility) by Assay — 23.81; 22.30 mg/dl
Phase 2 N=130 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
Untreated Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS): Time to Event — 221; 213; 361; 337 days
N/A N=130 An Innovative Treatment for Cervical Pre Cancer
Cervical Intraepithelial Neoplasia
Primary: Mean Depth of Necrosis Achieved With the LMIC-adapted CryoPen and the Thermocoagulator Compared to Mean Depth of Necrosis Achieved With CO2-based Cryotherapy — 6.0; 5.6…
N/A N=6 Proton Beam Re-Irradiation in Thoracic Cancers
Metastatic Malignant Neoplasm in the Lung · Recurrent Disease · Thoracic Neoplasm
Primary: Number of Participants With Grade 3 or Greater Toxicity Attributable to Radiation Treatment — 2 Participants
Phase 3 N=730 Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Diabetes Mellitus, Type 1
Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 — 0.09; -0.44; -0.44 Percentage (%) — p=<0.0001
Phase 3 N=221 Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
Mild Cognitive Impairment (MCI)
Primary: Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R) — 1; 9 Participants — p=.02
Phase 2 N=165 A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 7.69; 7.75 months — p=0.248
Phase 2 N=30 Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: The Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 1 participants
N/A N=140 Immersive Virtual Reality Intervention for Non-Opioid Pain Management: A Randomized Controlled Trial
Pain · Pain Management
Primary: Pain Intensity Ratings (NRS) — 4.66; 4.94 score on a scale
Phase 1 N=24 Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function
Infections, Bacterial
Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter
Early Phase 1 N=6 Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Blood Brain Barrier Defect
Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC